TCL Archive Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules July 30, 1999
TCL Archive FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview. November 7, 2003